West Pharma v. Advcare Medical: ITC Finds Violation After 669-Day Investigation
West Pharmaceutical Services IL, Ltd. brought a Section 337 complaint at the U.S. International Trade Commission against Advcare Medical, Inc., asserting four patents covering liquid transfer devices and vial adapters used in drug delivery. After a 669-day investigation, ALJ Clark Cheney found a violation — delivering a full merits judgment for the patent holder.
ITC delivers Section 337 infringement verdict for West Pharma drug delivery patents
West Pharmaceutical Services IL, Ltd. filed Investigation No. 337-TA-1362 at the United States International Trade Commission on April 6, 2023, naming Advcare Medical, Inc. as the sole respondent. The complaint asserted four patents — two utility-adjacent design registrations (USD765837, USD630732, USD767124) and one utility patent (US10688295B2) — covering liquid transfer devices with integral vial adapters and female connectors used in pharmaceutical infusion and drug delivery applications. The proceeding was presided over by Administrative Law Judge Clark Cheney in Washington, D.C.
The investigation closed on February 3, 2025, with a finding of violation and a judgment on the merits in favour of West Pharma. In ITC Section 337 proceedings, a violation finding typically triggers remedial orders — most commonly a Limited Exclusion Order barring importation of infringing products and a Cease and Desist Order against domestic sale and distribution. The public record does not detail the specific remedial orders issued following the violation finding, but the merits judgment leaves Advcare Medical with constrained options for continued U.S. market access.
The 669-day duration aligns with typical contested ITC investigations involving multiple patents and detailed technical records in the life sciences device sector. The decision to pursue four patents simultaneously — including three design patents — suggests West Pharma sought broad exclusionary coverage across form and function. The involvement of Blank Rome LLP for the plaintiff and a single named agent for the defence, with no defendant law firm on record, is consistent with an asymmetric litigation posture that may have contributed to the outcome. The underlying commercial rationale — protecting a liquid transfer and vial adapter platform against lower-cost imported alternatives — reflects a recurring enforcement pattern in the medical device supply chain.
Filing to Judgment on the merits for Plaintiff in 669 days
669-day ITC investigation, consistent with complex multi-patent Section 337 proceedings
ITC violation found: what the merits judgment means for both parties
What a Section 337 violation finding means in practice
A violation finding by the ITC ALJ under Section 337 of the Tariff Act establishes that the respondent’s imported products infringe valid and enforceable U.S. intellectual property. The finding is submitted to the full Commission for review, which then determines remedial orders. The standard remedy is a Limited Exclusion Order (LEO) barring importation of infringing goods at the U.S. border, enforced by U.S. Customs and Border Protection.
Import ban exposureWest Pharma secures enforcement leverage over its device platform
A merits judgment for West Pharma confirms the validity and infringement of its liquid transfer device and vial adapter patents across both utility and design dimensions. An ITC exclusion order, if issued following Commission review, would block Advcare Medical’s infringing imports at the U.S. border — a commercially significant remedy that does not require ongoing district court enforcement. This outcome also strengthens West Pharma’s negotiating position against other potential infringers in the medical device supply chain.
Exclusion order leverageAdvcare Medical faces import exclusion and domestic sale restrictions
With a violation finding on the merits, Advcare Medical is exposed to a Limited Exclusion Order barring importation of the infringing liquid transfer devices and vial adapters, as well as a potential Cease and Desist Order covering domestic inventory. Appeal lies to the U.S. Court of Appeals for the Federal Circuit, but the standard of review is deferential. Absent a successful appeal or design-around, continued U.S. market access for these product lines is significantly at risk.
Market access at riskDesign and utility patent stacking raises the bar for vial adapter suppliers
West Pharma’s enforcement strategy — asserting three design patents alongside a utility patent in a single ITC investigation — signals a layered IP posture that is increasingly common in the medical device sector. This approach makes design-arounds significantly more complex, as a competitor must clear both the ornamental appearance and the functional architecture of the patented system. Other importers of liquid transfer and vial adapter products should treat this outcome as a meaningful enforcement signal.
Multi-patent stacking riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | West Pharma. Services IL, Ltd. | Company | Pharmaceutical device manufacturer — holder of USD765837, USD630732, USD767124, and US10688295B2Search in Eureka ↗ |
| Defendant | Advcare Medical, Inc | Company | Advcare Medical, Inc. — importer of liquid transfer devices and vial adapters named as ITC respondentSearch in Eureka ↗ |
| Plaintiff counsel | Domingo M. Llagostera | Attorney | Counsel for West Pharma. Services IL, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Blank Rome LLP | Law Firm | Representing West Pharma. Services IL, Ltd.Search in Eureka ↗ |
| Defendant counsel | Meng Tung Tan | Attorney | Counsel for Advcare Medical, IncSearch in Eureka ↗ |
| Presiding judge | Judge Clark Cheney | Judge | United States International Trade CommissionSearch in Eureka ↗ |
Official order — verbatim text
The verdict entry — ‘Participant Disposition: Violation Found’ with a basis of ‘Judgment on the merits for Plaintiff’ — reflects a full adjudication on infringement and validity under Section 337 of the Tariff Act. This is not a procedural default or consent order; it indicates that the ALJ assessed the technical merits of all four asserted patents against Advcare Medical’s products and found infringement. For West Pharma, this disposition establishes the factual and legal foundation for Commission-level remedial relief. For Advcare Medical, the merits finding raises the evidentiary bar for any Federal Circuit appeal.
USD765837, USD630732, USD767124 & US10688295B2 — Liquid Transfer Device and Vial Adapter IP
The four patents at issue span both ornamental design and functional utility dimensions of West Pharma’s liquid transfer device platform. USD765837, USD630732, and USD767124 are U.S. design patents protecting the distinctive visual appearance of the liquid transfer device and vial adapter products — registered under applications US29/478726, US29/344390, and US29/478723 respectively. US10688295B2 is a utility patent (application US14/910347) covering the functional architecture of the liquid transfer system, including the mechanisms enabling safe, needleless transfer between vials and infusion containers.
West Pharma’s decision to assert both design and utility patents in a single ITC complaint reflects a portfolio strategy designed to eliminate design-around options. The products at issue — liquid transfer devices with integral vial adapters and female connectors — are widely used in hospital pharmacy and infusion therapy workflows. Competitors seeking to supply the U.S. market with functionally equivalent products face a multi-layered clearance challenge: they must avoid infringing the ornamental design claims while also clearing the utility patent’s functional scope. This combination substantially raises the barrier to entry for low-cost importers in the pharmaceutical device sector.
Should you run an FTO against USD765837, USD630732, USD767124, and US10688295B2?
Any company manufacturing, importing, or distributing liquid transfer devices, vial adapters, or needleless infusion connectors for the U.S. market should treat this ITC outcome as a direct trigger for freedom-to-operate analysis. The violation finding against Advcare Medical confirms that West Pharma will actively enforce this portfolio at the ITC — a venue that can result in import bans enforceable at the U.S. border without a damages threshold. Product teams developing or sourcing competing vial adapter and liquid transfer systems should assess both the ornamental design scope and the utility claim set before U.S. launch or distribution.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US10688295B2 against your product’s functional architecture and cross-reference the design patent family to identify design-around white space. Eureka’s citation analysis surfaces related West Pharma applications and any continuation risk, while the ITC enforcement database flags active and prior Section 337 investigations in the pharmaceutical device space. Teams can generate a structured FTO report directly within Eureka, reducing outside counsel time on initial clearance.
Run a freedom-to-operate analysis on USD0765837S to assess your product’s exposure
Run FTO in Eureka →Section 337 cases involving medical device and drug delivery patents at the ITC
Explore ITC investigations asserting design and utility patents in the pharmaceutical device and liquid transfer system space, including prior Section 337 proceedings before the U.S. International Trade Commission.
What this case signals for the medical device and drug delivery IP landscape
West Pharma’s ITC win reinforces design-plus-utility stacking as a dominant enforcement strategy in pharmaceutical device importation.
ITC is the preferred venue for medical device import enforcement
The Section 337 route gives patent holders a faster path to import exclusion than district court litigation, with no damages requirement. For device companies with established manufacturing outside the U.S., an ITC exclusion order is often more commercially disruptive than a monetary judgment. This case reinforces the ITC’s role as a primary enforcement venue in the pharmaceutical device supply chain.
Combining design and utility patents in a single ITC complaint maximises coverage
West Pharma’s use of three design patents alongside one utility patent in the same investigation is a deliberate strategy to cover both ornamental and functional dimensions. Respondents cannot easily design around ornamental claims while preserving function. Companies importing competing liquid transfer or vial adapter products should audit their exposure across both patent types before entering the U.S. market.
West v Advcare — key questions answered
The ITC found a Section 337 violation and entered judgment on the merits for plaintiff West Pharmaceutical Services IL, Ltd. The investigation, filed April 6, 2023 and closed February 3, 2025, covered four patents — USD765837, USD630732, USD767124, and US10688295B2 — asserted against Advcare Medical’s liquid transfer and vial adapter products.
West Pharma asserted four patents: design patents USD765837 (App. US29/478726), USD630732 (App. US29/344390), and USD767124 (App. US29/478723), covering the ornamental appearance of liquid transfer devices and vial adapters, plus utility patent US10688295B2 (App. US14/910347) covering the functional architecture of liquid transfer devices for pharmaceutical infusion applications.
Following a violation finding, the ITC Commission typically issues a Limited Exclusion Order (LEO) barring importation of the infringing products, enforced by U.S. Customs and Border Protection, and/or a Cease and Desist Order covering domestic sale and distribution of existing inventory. The specific remedial orders in 337-TA-1362 are subject to Commission review of the ALJ’s initial determination.
The ITC cannot award monetary damages but can issue exclusion orders that block infringing goods at the U.S. border — often a more commercially disruptive remedy for import-dependent respondents. Proceedings are typically faster than district court litigation, and there is no jury. The Section 337 violation standard requires domestic industry, importation, and infringement of a valid U.S. intellectual property right.
Yes. Following Commission review, Advcare Medical may appeal to the U.S. Court of Appeals for the Federal Circuit. However, the Federal Circuit applies a deferential standard of review to ITC factual findings on infringement and validity. A successful appeal would require demonstrating legal error in the ALJ or Commission’s analysis, which is a high bar given a full merits adjudication on four patents.
PatSnap Eureka searches patents and litigation data to answer instantly.